Discovery of new 6-ureido/amidocoumarins as highly potent and selective inhibitors for the tumour-relevant carbonic anhydrases IX and XII
Journal of Enzyme Inhibition and Medicinal Chemistry · 2023
DOI: 10.1080/14756366.2022.2154603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. Verfasst von Ashraf K El-Damasy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, South Korea. Hauptthemen laut MEDLINE: Carbonic Anhydrases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Government, Korea Research Fellowship Program, Ministry of Science and ICT.
Abstract (Originalsprache)
A series of 6-ureido/amidocoumarins (5a-p and 7a-c) has been designed and synthesised to develop potent and isoform- selective carbonic anhydrase hCA XI and XII inhibitors. All coumarin derivatives were investigated for their CA inhibitory effect against hCA I, II, IX, and XII. Interestingly, target coumarins potently inhibited both tumour-related isoforms hCA IX (KIs: 14.7-82.4 nM) and hCA XII (KIs: 5.9-95.1 nM), whereas the cytosolic off-target hCA I and II isoforms have not inhibited by all tested coumarins up to 100 μM. These findings granted the target coumarins an excellent selectivity profile towards both hCA IX and hCA XII isoforms, supporting their development as promising anticancer candidates. Moreover, all target molecules were evaluated for their anticancer activities against HCT-116 and MCF-7 cancer cells. The 3,5-bis-trifluoromethylphenyl ureidocoumarin 5i, exerted the best anticancer activity. Overall, ureidocoumarins, particularly compound 5i, could serve as a promising prototype for the development of potent anticancer CAIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Section of Pharmaceutical and Nutraceutical Sciences, Department of NEUROFARBA, University of Florence, Florence, Italy.
- Laboratory of Molecular Modeling Cheminformatics & QSAR, Department of NEUROFARBA-Pharmaceutical and Nutraceutical Section, University of Firenze, Florence, Italy.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafr El Sheikh, Egypt.
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul, South Korea.
ORCID-Profile: Alessio Nocentini, Wagdy M Eldehna, Claudiu T Supuran
Förderung
- Korea Government
- Korea Research Fellowship Program
- Ministry of Science and ICT
- Korea Institute of Science and Technology
Zitieren
APA
El-Damasy, A. K., Kim, H. J., Nocentini, A., Seo, S. H., Eldehna, W. M., Bang, E. K., Supuran, C. T., & Keum, G. (2023). Discovery of new 6-ureido/amidocoumarins as highly potent and selective inhibitors for the tumour-relevant carbonic anhydrases IX and XII. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2022.2154603
Vancouver
El-Damasy AK, Kim HJ, Nocentini A, Seo SH, Eldehna WM, Bang EK, et al. Discovery of new 6-ureido/amidocoumarins as highly potent and selective inhibitors for the tumour-relevant carbonic anhydrases IX and XII. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023. doi:10.1080/14756366.2022.2154603
BibTeX
@article{ElDamasy2023,
author = {El-Damasy, Ashraf K and Kim, Hyun Ji and Nocentini, Alessio and Seo, Seon Hee and Eldehna, Wagdy M and Bang, Eun-Kyoung and Supuran, Claudiu T and Keum, Gyochang},
title = {Discovery of new 6-ureido/amidocoumarins as highly potent and selective inhibitors for the tumour-relevant carbonic anhydrases IX and XII},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2023},
doi = {10.1080/14756366.2022.2154603}
}
EUVIMED